Transdermal selegiline in HIV-associated cognitive impairment: Pilot, placebo-controlled study

The authors conducted a pilot randomized, double-blind, placebo-controlled clinical trial of the transdermal administration of selegiline in HIV+ pati ents to obtain preliminary data to assess its safety, tolerability, and imp act on HIV-associated cognitive impairment. Both selegiline and placebo wer e well tolerated with few adverse events. Improvements favoring the selegil ine group were suggested on single tests of verbal memory and motor/psychom otor performance, warranting a larger study.